Lipiduce

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lipiduce

Lipiduce is a prescribed medicinal product whose single active ingredient is Atorvastatin Calcium, utilized primarily as a synthetic antilipemic agent to manage elevated blood lipid levels. As a specific brand of Atorvastatin, it is classified within the group of HMG-CoA Reductase Inhibitors, commonly known as statins.

Property Description
Active ingredient Atorvastatin Calcium
Form Film-Coated Tablet (Oral Solid Dose)
Pharmacological class HMG-CoA Reductase Inhibitor (Statin)
Common use Management of high blood lipid levels
Origin Synthetic Compound

What Type of Medicine is Lipiduce and Its Pharmacological Class?

Lipiduce belongs to the class of HMG-CoA Reductase Inhibitors, a group of medicines that are widely recognized as statins. This classification means its therapeutic action is focused on modulating the body's internal synthesis of lipids. The established use of statins as a first-line treatment is clinically recognized for its critical role in modifying the course of chronic conditions like hypercholesterolemia and various forms of dyslipidemia.


Composition, Origin, and Pharmaceutical Form

  • The core component of Lipiduce is Atorvastatin Calcium, a synthetic compound that is stable and effective upon oral route administration. The active substance, Atorvastatin, is recognized as being on the Model List of Essential Medicines. This international designation refers to the efficacy and reliability of the medication as a standard in lipid regulation.
  • The pharmaceutical preparation is an oral solid dose, typically supplied as a film-coated tablet designed for systemic absorption following ingestion. Lipiduce is generally used for adults requiring long-term lipid management.

How Does Lipiduce Reduce Cholesterol Levels?

Lipiduce works by performing selective competitive inhibition of the HMG-CoA reductase enzyme within the liver, blocking the critical rate-limiting step in the production of new cholesterol. This action reduces internal cholesterol synthesis and, concurrently, triggers the upregulation of LDL receptors on liver cells. The overall general purpose of this mechanism is twofold: decreasing the amount of cholesterol the body makes and increasing the cellular clearance of existing Low-Density Lipoprotein (LDL) cholesterol (often referred to as 'bad' cholesterol) from the blood, thereby normalizing the concentration of circulating lipids.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Lipiduce?

Possible Side Effects and Safety Information

Lipiduce (fenofibrate) is associated with a range of possible side effects and requires specific safety monitoring.

Serious and Clinically Significant Adverse Reactions

The most serious safety concerns documented in regulatory information include hepatotoxicity (drug-induced liver injury, including rare cases leading to liver transplantation or death), myopathy (muscle disease), and rhabdomyolysis (severe muscle breakdown that can cause renal failure). The risk of muscle toxicity is notably increased when Lipiduce is taken with a statin, particularly in geriatric patients or those with pre-existing kidney impairment or hypothyroidism.

Other significant adverse events include pancreatitis, cholelithiasis (gallstone formation), and venothromboembolic disease (e.g., pulmonary embolism and deep vein thrombosis). Severe acute and delayed hypersensitivity reactions, such as anaphylaxis and Stevens-Johnson syndrome, have also been reported.

Common Adverse Reactions and Safety Monitoring

Common adverse reactions, reported in clinical trials at an incidence ge 2% and greater than placebo, include abnormal liver tests (increased AST/ALT), increased creatine phosphokinase (CPK), and rhinitis (runny nose). Transient and reversible increases in serum creatinine have also been observed, requiring periodic renal function monitoring, especially in patients with pre-existing impairment.

Due to these risks, Lipiduce is contraindicated in patients with severe renal impairment, active liver disease (including unexplained persistent function abnormalities), and pre-existing gallbladder disease. Periodic monitoring of liver function tests (ALT/AST) and renal function is required during therapy. Patients should be closely monitored for signs of muscle pain or tenderness, which may signal the onset of serious muscle disorders.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Lipiduce (Atorvastatin Calcium) overdose does not describe a specific, characteristic acute symptom profile. Clinical data regarding overexposure is limited, with management focused entirely on professional medical monitoring and general supportive care.

Immediate Emergency Actions

Any suspected overexposure to Lipiduce requires immediate emergency medical attention. Contact emergency services immediately if the affected individual has collapsed, has a seizure, is experiencing trouble breathing, or cannot be awakened. Professional clinical guidance must be sought in all cases of suspected overdose to allow for continuous observation and to manage any potential progression to serious outcomes.

Management Classification Official Statement
Documented Symptoms No specific acute manifestations are formally documented in the official overdose section.
Antidote Availability No specific antidote is known for Atorvastatin overdosage.
Clearance Utility Haemodialysis is not expected to be an effective measure due to the drug’s extensive plasma protein binding.
Mandated Treatment Management involves symptomatic and supportive measures; procedures such as gastric lavage may be considered by healthcare professionals.

The regulatory profile dictates that because treatment is limited to supportive measures and there is no known antidote, close professional monitoring and continuous clinical observation are required. This approach is mandated to track the patient's condition and address underlying physiological issues that may arise from overexposure.

Therapeutic Uses of Lipiduce

Lipiduce (Atorvastatin) is commonly used across therapeutic domains where additional symptomatic support is needed to address elevated blood lipids. This medication is relevant for managing chronic conditions characterized by high concentrations of LDL cholesterol and triglycerides. The medication is generally applied in scenarios involving primary hypercholesterolemia, mixed dyslipidemia, and for patients requiring cardiovascular event risk management. This treatment is used for managing the underlying risk factor, which may assist with maintaining functional stability and support general well-being during symptomatic phases.

The primary long-term therapeutic benefit is relevant for easing the risk associated with severe vascular conditions that require supportive management. This treatment is considered relevant when supportive management is appropriate for conditions associated with symptoms that interfere with daily functioning due to underlying vascular stress. It supports the patient by helping to ease the overall symptomatic burden of chronic internal risk. Use is also relevant for high-risk groups, including patients with Type 2 Diabetes Mellitus or adolescent patients diagnosed with genetic conditions like Familial Hypercholesterolemia.

Quick Fact: Supportive Management for Physiological Stress
Lipiduce is applied in addressing conditions marked by increased physiological stress, which may assist with maintaining functional stability and support general well-being.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lipiduce?

Lipiduce (Atorvastatin Calcium) eligibility is strictly defined by regulatory documents, focusing on patient status rather than therapeutic benefit. Absolute Contraindications prohibit its use in certain populations.

Contraindicated Populations

The medicine is contraindicated for patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels, as established by the FDA and EMA. Additionally, it is prohibited for women who are pregnant or breastfeeding, and women of childbearing potential are advised to use effective contraception during treatment. Use is also excluded for individuals with a known hypersensitivity to Atorvastatin.

Age and Condition Limitations

Population Group Eligibility Status
Adults (18+ years) Eligible for approved uses.
Children (< 10 years) Safety and efficacy have not been established.
Pediatric (10–17 years) Use is restricted to specific conditions, such as Familial Hypercholesterolemia.
Renal Impairment Caution is advised, as it is a risk factor for myopathy.

Advanced age and conditions like uncontrolled hypothyroidism are listed as risk factors for myopathy, requiring clinical caution.

What should I know about interactions with other medicines?

Lipiduce contains ezetimibe and is often used in combination with statin medications, which can affect its potential for interaction with other drugs. It is crucial to inform your healthcare provider about all prescription and over-the-counter medicines, vitamins, and herbal supplements you are currently taking.

Medications That May Interact with Lipiduce

Certain combinations of medicines may increase the risk of side effects, particularly muscle-related issues like myopathy or rhabdomyolysis, or may alter the effectiveness of one or both drugs. Your doctor may need to adjust the dosage or monitor you more closely if you are taking Lipiduce with any of the following:

Interacting Drug Class/Name Potential Concern Clinical Consideration
Statins (e.g., Atorvastatin, Simvastatin, Rosuvastatin) Increased risk of muscle side effects. Close monitoring is necessary.
Fibrates (e.g., Fenofibrate, Gemfibrozil) Increased risk of muscle side effects and gallstones. Use with caution; monitor for symptoms.
Bile Acid Sequestrants (e.g., Cholestyramine) May significantly reduce Lipiduce absorption. Take Lipiduce at least 2 hours before or 4 hours after the sequestrant.
Cyclosporine Increased exposure to both Lipiduce and Cyclosporine. Monitor blood concentrations of Cyclosporine.
Warfarin and other oral anticoagulants May increase the blood-thinning effect. Frequent monitoring of International Normalized Ratio (INR) is recommended.

Other Products and Lifestyle

While there are generally no significant interactions between Lipiduce and food, alcohol consumption should be discussed with your doctor, especially in patients with a history of liver problems, as excessive use may increase the risk of liver enzyme elevation and pancreatitis.

Mechanism of Action

Direct Inhibition of Hepatic Cholesterol Synthesis

The mechanism begins in the liver, where Lipiduce acts as a selective competitive inhibitor of the enzyme HMG-CoA Reductase . This enzyme is the primary rate-limiting enzyme in the mevalonate pathway that catalyzes a step in cholesterol synthesis. By binding to the active site, the drug prevents the conversion of HMG-CoA into mevalonate, which is the first committed step in the synthesis pathway. This action causes a rapid depletion of cholesterol within the liver cell itself.

Enhanced Systemic Clearance via LDL Receptor Upregulation

The resulting drop in internal cholesterol concentration triggers a compensatory feedback loop: the liver cell dramatically upregulates the expression of LDL receptors on its surface. These receptors function to capture and clear Low-Density Lipoprotein cholesterol (LDL-C) particles circulating in the bloodstream. This accelerated clearance and catabolism of circulating lipoproteins is the key physiological action that results in a reduction of plasma LDL-C concentrations.

Pleiotropic Modulation of Vascular Function

Beyond the primary lipid-modulating cascade, the drug exerts pleiotropic effects that involve mechanisms distinct from its primary lipid-modulating action. By interfering with the synthesis of mevalonate pathway intermediates (isoprenoids), the drug modulates the function of small signaling proteins (like Rho and Rac). This mechanism modulates signaling proteins that affect endothelial function and local inflammatory processes within the vessel wall.

Dosage and Administration Information

Official Administration Guidelines

Lipiduce (Atorvastatin Calcium) is strictly administered via the oral route as a film-coated tablet in strengths ranging from 10 mg to 80 mg. The medication is designed for chronic (long-term) daily use and must be implemented as an adjunct to a consistent cholesterol-lowering diet.

Dosing and Scheduling

Administration Scope Official Labeled Instruction
Route of Administration Oral
Dosing Schedule (Adults) Initial doses are typically 10 mg or 20 mg once daily. For patients requiring substantial LDL-C reduction (>45%), the initial dose may be 40 mg once daily. The maximum dose is 80 mg once daily.
Frequency and Titration Taken once daily. Dose adjustments must be made at intervals of 4 weeks or more to assess patient response.
Timing and Food Context The tablet may be administered as a single dose at any time of the day, and ingestion is permissible with or without food.

Population and Procedural Rules

Age-Group Administration Rules

  • Renal Impairment: No dosage adjustment is required.
  • Pediatric Use (HeFH, ages 10+): The starting dose is 10 mg once daily, with a maximum recommended dose of 20 mg per day.

Missed-Dose Rules If an oral dose is missed, the patient should take it as soon as possible, but if the dose is missed by more than 12 hours, the missed dose must be skipped, and the regular once-daily schedule should be resumed. Doubling doses is not recommended.

Connection to the Overall Use Protocol

The protocol establishes Lipiduce as a fixed-dose, once-daily oral tablet intended for chronic therapy. This structure ensures the medication maintains a stable therapeutic level, while the mandated four-week titration period defines the timeframe for any dose modification. The instructions provide flexibility regarding daily timing and food intake but define the maximum allowable dose and the necessary steps for managing a missed dose.

Recent Clinical Evidence

Lipiduce: Recent Clinical Evidence

Research examined Lipiduce across several areas, primarily using short-term randomized controlled trials (RCTs) to explore symptom patterns over defined time intervals.

For Schizophrenia, studies involved adult patients experiencing periods of heightened symptoms. The research focused on changes in symptom intensity using standardized scales like the PANSS. Findings describe patterns observed in the studies, with reported numeric measurements of changes in scores between the active study group and the comparison group over short durations.

In Bipolar I Disorder (Acute Manic or Mixed Episodes), research examined Lipiduce in studies involving adults during acute, fluctuating episodes. Studies monitored severity scales, such as the Young Mania Rating Scale (YMRS), over periods typically lasting 3 to 4 weeks. Data show patterns related to how symptom intensity evolved within the observed groups during this acute phase.

Lipiduce was also explored in studies involving Major Depressive Disorder as an adjunct to existing treatments, and in pediatric patients for Autism Spectrum Disorder (Irritability) and Tourette's Disorder, with research consistently focusing on short-term symptom changes.

What is Still Uncertain About Lipiduce

Long-term effects are not fully established across indications. Follow-up durations were limited, and limited information is available for long-term outcomes related to sustained daily functioning or activity level. Data are still emerging, and research is ongoing, but for now, results apply only to the specific populations studied in the short-term acute settings. Comparative evidence and subgroup findings remain uncertain in several areas.

Key Studies & References

  1. Aripiprazole as Adjunctive Therapy for Patients with Major Depressive Disorder: Overview and Implications of Clinical Trial Data

Frequently Asked Questions (FAQ)

Common questions about Lipiduce (FAQ)


Q: Can Lipiduce be used for things other than high lipid levels?

Official documents state that the primary purpose of Lipiduce is to manage high cholesterol and triglycerides. However, the medication is also specifically approved for patients at high risk of heart disease to help reduce the risk of future cardiovascular events. Its use is officially documented for both managing lipid levels and for cardiovascular risk modification in certain patients.


Q: Does Lipiduce treat high triglycerides, high LDL, or both?

According to the official product information, Lipiduce acts to reduce both Low-Density Lipoprotein (LDL) cholesterol, often called “bad cholesterol,” and high triglycerides in the bloodstream. It also has an effect on increasing High-Density Lipoprotein (HDL) cholesterol, sometimes called “good cholesterol.” This action targets the overall imbalance of lipids (fats) in the blood.


Q: Is it okay to take Lipiduce with common vitamins or supplements?

Regulatory information indicates that there are generally no reported interactions with common, daily vitamins. However, patients are generally advised to inform their healthcare provider about all supplements and herbal remedies they are taking before starting Lipiduce. Discussing this with a healthcare provider helps ensure a complete understanding of one's current routine and potential for interaction.


Q: Can I stop taking Lipiduce once my cholesterol levels are better?

Official documents describe Lipiduce as a therapy intended for long-term use to help maintain lipid control and reduce cardiovascular risk. It is typically intended for long-term use and maintenance, not necessarily stopped once lipid goals are reached. Changes to the duration or discontinuation of therapy are decisions that are determined in consultation with a prescribing physician.


Q: Can certain herbal remedies or teas interact with Lipiduce?

Yes, the official product information notes that certain food and herbal substances can interact with the medication. For example, large amounts of grapefruit products or certain herbal supplements may increase the risk of side effects or change the drug's effectiveness. It is important that any consumption of herbal remedies or teas is disclosed to a physician before starting Lipiduce.


Q: Why is Lipiduce prescribed for people who seem otherwise healthy?

Lipiduce is often prescribed to people who appear healthy but possess multiple cardiac risk factors, such as high LDL cholesterol, high blood pressure, or diabetes. Studies indicate that reducing high cholesterol in these individuals actively helps to prevent the occurrence of major cardiovascular events. The medication is used to modify the risk of future cardiovascular events.


Q: Do the side effects of Lipiduce usually go away over time?

Official prescribing information indicates that for certain common and mild side effects, such as nausea or headache, symptoms may decrease or stop completely as the body adjusts to the medication. Any persistent, severe, or concerning side effects should be brought to the attention of a prescribing physician.


Q: Has anyone experienced nausea or stomach issues with Lipiduce?

Yes, regulatory documents list both nausea and abdominal pain as common adverse effects reported by patients taking the medication in clinical trials. Significant or persistent stomach issues should be communicated to a healthcare professional.


Q: Can taking Lipiduce cause joint stiffness or back pain?

According to official sources, joint pain and lower back pain are listed among the common side effects reported by some patients. New or worsening muscle or joint symptoms are typically communicated to a healthcare provider.


Q: Is it normal to feel tired when you first start taking Lipiduce?

The official product information does not list minor fatigue as a common, expected side effect. However, unusual tiredness or weakness is noted as a potential symptom of a more serious, though rare, muscle-related condition. Any sign of unusual fatigue, particularly when combined with muscle pain, is typically reported to a physician promptly.


Q: Does Lipiduce interact with blood pressure medications?

Yes, official documents indicate that the medication may interact with certain types of blood pressure medication, specifically some calcium channel blockers like diltiazem or verapamil. These combinations can potentially increase the risk of side effects from Lipiduce. Adjustments to the dose or closer clinical monitoring may be implemented when these medicines are used together.


Q: Is it safe to use over-the-counter pain relievers while on Lipiduce?

The drug label does not list reported interactions with common over-the-counter pain relievers such as acetaminophen or ibuprofen. However, regulatory warnings exist regarding the risk of liver injury associated with both high doses of acetaminophen and Lipiduce, requiring caution. Consultation with a healthcare professional regarding the concurrent use of any medication is recommended.


Q: Are there certain antibiotics or antifungals that interact with Lipiduce?

Yes, official prescribing information lists specific classes of medicines, including certain macrolide antibiotics and azole antifungals, that interact with Lipiduce. Official instructions indicate that the dose of Lipiduce may be adjusted or closely monitored when used with these interacting medicines.


Q: What does the official patient information say about Lipiduce for people with diabetes?

The regulatory label notes that changes in blood sugar control, specifically increases in HbA1c and fasting serum glucose levels, have been reported with statin-class medications. Official information suggests that for patients with diabetes, closer monitoring of blood glucose levels is typically part of the treatment protocol.


Q: Are there studies about Lipiduce and cardiovascular risk reduction?

Yes, the medication's ability to lower cardiovascular risk has been extensively studied in large, well-known clinical trials. These studies examined the drug's use in both primary prevention (patients at risk but without existing disease) and secondary prevention (patients who have already had a cardiovascular event).


Q: Is there a generic version of Lipiduce available?

Yes, Lipiduce is a brand name, and its generic version, atorvastatin, is widely available. The generic medication is available in the same tablet strengths as the brand-name product.


Q: Can Lipiduce cause problems with sleep?

The official label may list insomnia or general sleep disorders as a reported side effect in some patients. Persistent changes in sleep patterns after starting the medication are typically discussed with a healthcare professional.


Q: Is Lipiduce safe for people who have had a heart attack?

Yes, studies confirm the use of this therapy in individuals who have experienced an acute cardiovascular event, such as a heart attack. The use of Lipiduce in this context is established to help reduce the risk of future events.


Q: Does Lipiduce impact fertility or hormone levels?

Official documents note that the medication can increase the plasma levels of components found in oral contraceptives, specifically ethinyl estradiol and norethindrone. Furthermore, Lipiduce is officially contraindicated (prohibited) for women who are pregnant or who may become pregnant, due to documented concerns about potential fetal harm.


Q: Are there any restrictions on strenuous exercise while taking Lipiduce?

No specific restriction or ban on strenuous exercise is noted in the official prescribing information. However, patients are advised to monitor for any new or unusual muscle pain or soreness, as this can be a side effect and, rarely, a sign of a serious muscle injury. Any significant, persistent muscle symptoms are typically reported to a physician.

How should Lipiduce be stored and disposed of?

Official Storage and Disposal Instructions for Lipiduce

The storage and disposal requirements for Lipiduce (Atorvastatin) are defined by official government regulations to maintain product stability and ensure environmental safety.

Storage Conditions and Stability

Lipiduce must be stored at room temperature, remaining below 30°C and away from excess heat and moisture; storage in areas like the bathroom is prohibited. The film-coated tablets must be protected from light and moisture and kept in the original container, tightly closed.

Requirement Classification
Temperature Below 30 C (Room Temperature)
Protection Protect from Light and Moisture
Shelf-Life 24 Months (Under specified conditions)

Child Safety and Disposal

For safety, the medicine must be stored out of the sight and reach of children, with all safety caps securely locked. Regarding disposal, the active ingredient is classified as harmful to aquatic life with long lasting effects. Therefore, the product should not be disposed of in household wastewater and must be discarded according to official local pharmaceutical waste protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lipiduce found in:

A-Z Index: